Loading
A phase 3 trial of Trastuzumab, Trastuzumab rezetecan, Adebrelimab, Capecitabine and Pembrolizumab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer is a phase 3 interventional study registered as NCT07679360 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 1000 participants planned, started 2026-09-02 and due to reach its primary completion in 2030-12. Interventions recorded: Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets and Pembrolizumab injection.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Early triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.